Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback